Table 5. Blood pressure measurements in randomised groups.
| Axitinib titration
|
Placebo titration
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | dBP | ΔdBP | sBP | ΔsBP | n | dBP | ΔdBP | sBP | ΔsBP | |
| Baseline | 56 | 76·7 (9·6) | ·· | 127·0 (13·6) | ·· | 56 | 77·9 (8·0) | ·· | 126·5 (13·1) | ·· |
|
| ||||||||||
| Cycle 1 day 1 | 52 | 75·0 (8·1) | –1·6 (8·2) | 123·1 (13·3) | –4·3 (11·1) | 51 | 76·0 (7·8) | –2·6 (7·4) | 123·6 (12·6) | –2·9 (9·2) |
|
| ||||||||||
| Cycle 1 day 15 | 56 | 81·5 (9·9) | 4·8 (8·5) | 130·9 (16·7) | 3·8 (12·2) | 56 | 81·0 (7·5) | 3·0 (7·7) | 130·5 (13·1) | 4·1 (12·5) |
|
| ||||||||||
| Cycle 2 day 1 | 56 | 80·9 (7·9) | 4·2 (9·0) | 129·0 (12·5) | 1·9 (12·4) | 56 | 81·5 (7·4) | 3·5 (8·0) | 127·3 (12·7) | 0·9 (13·6) |
|
| ||||||||||
| Cycle 2 day 15 | 55 | 82·4 (10·7) | 5·5 (10·5) | 130·7 (13·3) | 3·6 (13·8) | 55 | 82·3 (10·0) | 4·4 (10·7) | 129·2 (14·5) | 2·7 (16·6) |
|
| ||||||||||
| Cycle 3 day 1 | 48 | 83·9 (8·1) | 6·6 (8·3) | 131·5 (12·8) | 3·5 (15·1) | 49 | 83·9 (9·2) | 5·9 (9·3) | 134·1 (13·9) | 8·4 (15·4) |
|
| ||||||||||
| Cycle 4 day 1 | 45 | 85·0 (10·8) | 7·4 (8·2) | 132·3 (13·5) | 4·3 (12·7) | 48 | 82·5 (9·6) | 4·6 (8·5) | 129·2 (10·6) | 3·5 (13·0) |
|
| ||||||||||
| End of treatment | 35 | 75·2 (13·1) | 0·6 (10·8) | 127·6 (17·5) | 2·4 (17·0) | 44 | 81·1 (10·1) | 3·5 (6·3) | 128·5 (15·7) | 1·7 (14·0) |
|
| ||||||||||
| Follow-up | 16 | 72·5 (13·0) | –4·5 (10·1) | 124·2 (17·1) | –3·6 (16·9) | 25 | 77·8 (11·0) | –1·3 (8·5) | 127·2 (14·7) | –0·4 (16·3) |
Data are mean blood pressure, mm Hg (SD). SD=standard deviation. dBP=diastolic blood pressure. ΔdBP=change in diastolic blood pressure from baseline. sBP=systolic blood pressure;. ΔsBP=change in systolic blood pressure from baseline.